ANRO
Alto Neuroscience, Inc.
NYSE · Healthcare · Biotechnology · US
$22.65
−0.22%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$23.65
From 52W high−38.18%
Volume82096.00
Market cap$888.83M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$23.65
From 52W high
−38.18%
Volume
82096.00
Market cap
$888.83M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.0x
P/E (TTM)
—
RSI (14)
41.9
MomentumView details →
1D Return
−0.22%
YTD Return
+27.98%
SummaryUpdated Jun 1, 2026
Alto Neuroscience, Inc. (NASDAQ:ANRO) is a clinical-stage biopharmaceutical company founded in 2019 and based in Los Altos, California. The company went public in February 2024 and specializes in developing novel psychiatric medications using an innovative approach that combines artificial intelligence-enabled biomarkers with precision medicine. Alto focuses on addressing unmet medical needs in mental health disorders, particularly major depressive disorder, post-traumatic stress disorder, and cognitive impairment associated with schizophrenia.
Similar companies
Latest newsMore news →
Alto Neuroscience promoted Nick Smith to president and chief financial officer, effective August 26, 2026.69d agoAlto Neuroscience, Inc. (NYSE: ANRO) shares reached a new 52-week high of $36.99 during mid-day trading on Tuesday, with the last trade at $36.4220 and volume of 867,909 shares, after closing at $34.28 the previous day.71d ago